PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 24, 20260 citations

Therapeutic exploitation of the neonatal Fc receptor in albumin-based drug designs

View Full Paper
EAEugene Kusi AgyeiAarhus UniversityKHKenneth A. Howard

Key Points

  • This chapter aims to explore the role of the neonatal Fc receptor in drug design utilizing albumin.
  • Examined the function of the neonatal Fc receptor in maintaining immunoglobulin G and albumin levels.
  • Discussed cellular recycling mechanisms related to FcRn.
  • Identified potential applications of FcRn in albumin-based therapeutic strategies.
  • Highlighted the importance of FcRn in prolonging the half-life of albumin-associated drugs.
  • Demonstrated emerging therapeutic opportunities based on FcRn interactions.

Abstract

The neonatal Fc receptor (FcRn) plays a pivotal role in maintaining the homeostasis of immunoglobulin G and human serum albumin by diversion from lysosomal degradation by a cellular recycling mechanism. Leveraging this function, FcRn has been targeted to utilize albumin as a delivery platform, aiming to prolong the half-life of associated drugs. As our understanding of the FcRn expression profile in health and disease and diverse functions expands, new therapeutic opportunities emerge. This chapter addresses FcRn interactions, functional roles, with utilization for albumin-based drug strategies. Furthermore, we propose future directions for harnessing FcRn in drug designs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Agyei et al. (2025) studied this question.

synapsesocial.com/papers/69746187bb9d90c67120b577https://doi.org/10.1016/b978-0-443-27429-9.00024-4
Ask AI
Helpful
Bookmark
Share
View Full Paper